13h30 – 14h00Review of key efficacy resultsBernard Fourie
14h00 – 14h15Culture conversion as proxy marker of treatment outcomeKatya Kurbatova (remotely)
14h15 – 15h30DiscussionAll
15h30 – 16h00Tea break

From: Annex 3, Expert Group meeting on interim guidance for the use of delamanid in the treatment of multidrug-resistant tuberculosis

Cover of The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis
The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance.
Copyright © World Health Organization 2014.

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.